Table 4.
Effect of patient characteristics on the risk of not achieving SVR12/24 due to virological reasons
| Characteristics | No SVR/SVR12/24 (%) | Odds ratio | 95% CI | P |
|---|---|---|---|---|
| HCV genotype | ||||
| GT 3 | 22/1518 (1.4) | Ref. | — | — |
| GT 1 | 12/1444 (0.8) | 0.84 | 0.39‐1.70 | .634 |
| GT 2 | 11/1434 (0.8) | 0.66 | 0.30‐1.38 | .285 |
| GT 4 | 1/193 (0.5) | 0.61 | 0.03‐3.01 | .629 |
| GT 5‐6 | 1/50 (2.0) | 0.86 | 0.05‐4.41 | .881 |
| Compensated cirrhosis | ||||
| No | 27/3640 (0.7) | Ref. | — | — |
| Yes | 20/985 (2.0) | 2.53 | 1.38‐4.55 | .002 |
| Intravenous drug use a | ||||
| No | 8/1666 (0.5) | Ref. | — | — |
| Yes | 4/541 (0.7) | 1.35 | 0.34‐4.49 | .642 |
| PPI use at baseline | ||||
| No | 30/2389 (1.3) | Ref. | — | — |
| Yes | 5/445 (1.1) | 1.08 | 0.36‐2.62 | .870 |
| Treatment history | ||||
| Treatment‐naïve | 39/4124 (0.9) | Ref. | — | — |
| Treatment‐experienced | 8/530 (1.5) | 1.28 | 0.54‐2.66 | .543 |
| HIV/HCV coinfection | ||||
| No | 43/4267 (1.0) | Ref. | — | — |
| Yes | 4/176 (2.3) | 2.71 | 0.78‐7.26 | .072 |
Abbreviations: 95% CI, 95% confidence interval; GT, genotype; PPI, proton pump inhibitor; Ref., reference group; SVR12/24, sustained virological response 12/24 weeks after end of treatment.
Logistic regression analyses adjusted for cohort random effects were performed in a pooled subset of the effectiveness population with individual‐level data available and no missing data for each characteristic.
a
Current or past intravenous drug use. The definition of former drug use varied between cohorts with respect to timing and this level of detail was not available for most patients.